An evidence-based and risk-adapted GSF versus GSF plus plerixafor mobilization strategy to obtain a sufficient CD34+ cell yield in the harvest for autologous stem cell transplants-Reference-Cited by-同舟云学术

An evidence-based and risk-adapted GSF versus GSF plus plerixafor mobilization strategy to obtain a sufficient CD34+ cell yield in the harvest for autologous stem cell transplants

Published:2024-01 Issue: Volume:39 Page:101811
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Balint Milena Todorović,Lemajić Nikola^ORCID,Jurišić Vladimir,Pantelić Sofija,Stanisavljević Dejana^ORCID,Kurtović Nada Kraguljac,Balint Bela

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference50 articles.

1. Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-COV-2 pandemic. A report from the EBMT Activity Survey;Passweg;Bone Marrow Transplant.,2023

2. AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent;Cashen;Future Oncol.,2007

3. Mechanisms of G-CSF-mediated hematopoietic stem and progenitor mobilization;Greenbaum;Leukemia,2010

4. Egress and mobilization of hematopoietic stem and progenitor cells: a dynamic multi-facet process;Lapid,2008

5. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for blood and marrow transplantation;Mohty;Bone Marrow Transplant.,2014

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of apheresis outcomes in a cohort of Chilean patients treated with autologous stem cell transplantation: A single center real-world experience;Transfusion and Apheresis Science;2024-10

2. Sysmex XN-HPC: study of reference intervals and clinical decision limits in healthy allogeneic donors mobilised with G-CSF;Clinical and Experimental Medicine;2024-08-24

3. Advances in pharmacotherapy for sickle cell disease: what is the current state of play?;Expert Opinion on Pharmacotherapy;2024-07-02

4. Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?;Cells;2024-01-12